Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Hold” by Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has received a consensus recommendation of “Hold” from the seven ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $17.43.

Several equities analysts have commented on the company. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Barclays boosted their target price on shares of Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, September 23rd. Finally, Piper Sandler lowered their price target on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Monday, July 1st.

Insider Activity

In other news, CEO Jeffrey N. Simmons bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,500 shares of the stock in a transaction on Thursday, August 22nd. The shares were purchased at an average price of $14.85 per share, with a total value of $51,975.00. Following the acquisition, the director now directly owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jeffrey N. Simmons acquired 100,000 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was acquired at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the purchase, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. The disclosure for this purchase can be found here. 0.57% of the stock is owned by company insiders.

Institutional Trading of Elanco Animal Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELAN. Benjamin F. Edwards & Company Inc. lifted its stake in Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares during the period. ORG Partners LLC bought a new position in shares of Elanco Animal Health during the 2nd quarter worth approximately $31,000. nVerses Capital LLC bought a new position in shares of Elanco Animal Health during the 2nd quarter worth approximately $32,000. Jones Financial Companies Lllp acquired a new stake in Elanco Animal Health in the 4th quarter valued at $37,000. Finally, Quarry LP bought a new stake in Elanco Animal Health in the second quarter valued at $40,000. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $14.51 on Wednesday. The company has a quick ratio of 1.75, a current ratio of 2.93 and a debt-to-equity ratio of 0.92. Elanco Animal Health has a 12 month low of $8.52 and a 12 month high of $18.80. The company’s fifty day moving average is $14.11 and its 200-day moving average is $15.05. The firm has a market cap of $7.17 billion, a price-to-earnings ratio of -5.48, a price-to-earnings-growth ratio of 1.33 and a beta of 1.40.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. The company had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The business’s revenue was up 12.0% compared to the same quarter last year. During the same period last year, the company earned $0.18 earnings per share. Equities analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.